We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+21.98%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$679M
AUM Growth
+$8.14M
Cap. Flow
+$879K
Cap. Flow %
0.13%
Top 10 Hldgs %
38.68%
Holding
124
New
21
Increased
25
Reduced
15
Closed
25

Top Buys

Rank Stock Value
1
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$18.7M
2
IFRX icon
InflaRx
IFRX
+$13M
3
VSTM icon
Verastem
VSTM
+$7.91M
4
AVIR icon
Atea Pharmaceuticals
AVIR
+$7.58M
5
ELEV
Elevation Oncology
ELEV
+$6.86M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$21.5M
2
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$9.81M
3
BLUE
bluebird bio
BLUE
+$9.14M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.01M
5
MRNA icon
Moderna
MRNA
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.72%
2 Financials 6.8%
3 Real Estate 0.3%
4 Consumer Discretionary 0.15%
5 Utilities 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
51
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$3.65M 0.54%
89,650
– –
PHAT icon
52
Phathom Pharmaceuticals
PHAT
$692M
$3.58M 0.53%
+250,000
New +$2.88M
PRDS
53
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$3.52M 0.52%
1,945,206
+1,645,206
+548% +$3.01M
INSM icon
54
Insmed
INSM
$28.6B
$3.51M 0.52%
166,203
– –
BHVN icon
55
Biohaven
BHVN
$2.21B
$3.35M 0.49%
140,000
– –
FATE icon
56
Fate Therapeutics
FATE
$326M
$3.33M 0.49%
700,000
– –
USB icon
57
US Bancorp
USB
$99.6B
$3.3M 0.49%
+100,000
New +$3.23M
ALGS icon
58
Aligos Therapeutics
ALGS
$34.6M
$3.23M 0.48%
133,162
-3,830
-3% -$103K
NKTX icon
59
Nkarta
NKTX
$172M
$3.03M 0.45%
1,385,829
-400,000
-22% -$1.76M
MRTX
60
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.89M 0.43%
+80,000
New +$3.3M
SPRY icon
61
ARS Pharmaceuticals
SPRY
$612M
$2.74M 0.4%
409,463
– –
CVBF icon
62
CVB Financial
CVBF
$3.99B
$2.66M 0.39%
200,000
– –
ESPR
63
DELISTED
Esperion Therapeutics
ESPR
$2.57M 0.38%
1,850,000
– –
TECX
64
Tectonic Therapeutic
TECX
$585M
$2.57M 0.38%
225,417
+222,283
+7,093% +$2.51M
TSVT
65
DELISTED
2seventy bio
TSVT
$2.53M 0.37%
250,000
– –
LITS
66
Lite Strategy Inc
LITS
$30.9M
$2.38M 0.35%
361,084
+102,911
+40% +$654K
EGRX
67
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$2.31M 0.34%
118,857
+38,857
+49% +$922K
LIAN
68
DELISTED
LianBio American Depositary Shares
LIAN
$2.19M 0.32%
962,022
+752,422
+359% +$1.73M
AMLX icon
69
Amylyx Pharmaceuticals
AMLX
$2.54B
$2.16M 0.32%
100,000
– –
BKU icon
70
Bankunited
BKU
$3.36B
$2.15M 0.32%
100,000
– –
HRTX icon
71
Heron Therapeutics
HRTX
$92.9M
$2.15M 0.32%
1,850,000
+1,300,000
+236% +$2.32M
EQC
72
DELISTED
Equity Commonwealth
EQC
$2.03M 0.3%
100,000
– –
ARVN icon
73
Arvinas
ARVN
$572M
$1.99M 0.29%
80,000
– –
CHRS icon
74
Coherus Oncology
CHRS
$196M
$1.71M 0.25%
400,000
+200,000
+100% +$1.18M
EDIT icon
75
Editas Medicine
EDIT
$442M
$1.65M 0.24%
+200,000
New +$1.74M
1 2
3
4 5

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Tang Capital Management held 124 positions worth $679M, up 1.2% from $671M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tang Capital Management's Q2 2023 filing shows 21 new, 25 increased, 15 reduced and 25 closed positions. Its largest new stake was Rain Oncology Inc. Common Stock: 3,740,341 shares worth $4.49M. The largest sale was Novo Nordisk, an estimated $21.5M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Financials and Real Estate.

  • Tang Capital Management's largest Q2 2023 buy was Rain Oncology Inc. Common Stock: 3,740,341 shares worth $4.49M.
  • Tang Capital Management added most to Atea Pharmaceuticals in Q2 2023, an estimated $7.58M increase.
  • Tang Capital Management's biggest Q2 2023 reduction was bluebird bio, cutting an estimated $9.14M.
  • Tang Capital Management fully exited Novo Nordisk in Q2 2023, selling an estimated $21.5M.
  • Tang Capital Management's ten largest holdings make up 39% of its $679M portfolio in Q2 2023.
  • Tang Capital Management opened 21 new positions and closed 25 in Q2 2023.
  • Tang Capital Management's portfolio value rose 1.2% quarter-over-quarter to $679M.

Based on Tang Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.